A study published in the Journal of Translational Medicine reports that fratricide-driven, unedited CD7 CAR‑T cells demonstrate anti-leukemia activity against T‑cell malignancies. Researchers presented a manufacturing strategy that leverages natural fratricide among CD7-expressing T cells to produce effective CAR‑T products without genome editing. The approach could simplify production and reduce regulatory complexities tied to edited cell therapies while retaining potency against T‑cell leukemia. The paper highlights preclinical efficacy and early translational potential, positioning unedited CD7 CAR‑T as a candidate for rapid clinical evaluation in indications where CD7 is a validated target.